2025-04-20-PitchBook-新兴空间简报_长寿技术（英）_8页_425kb

Longevity Technology Summary

Overview

Longevity tech involves companies researching and developing therapies to combat aging by targeting its underlying biological mechanisms, aiming to increase lifespan and health span. Historically, it focused on treating age-related diseases, but recent advances in epigenetics and cellular reprogramming have shifted the focus to prevention rather than cure. Key areas include genomic instability, telomere attrition, and cellular senescence. Despite significant venture capital investment from sources like Jeff Bezos and Sam Altman, no breakthrough therapy has reached the market yet.

Historical Evolution

The field evolved from treating common age-related conditions like cardiovascular and neurodegenerative diseases to addressing core aging processes. Breakthroughs such as induced pluripotent stem cells (iPSCs) discovered in 2006 by Shinya Yamanaka demonstrated cell rejuvenation, leading to applications in regenerative medicine. Today, technologies emphasize preventing diseases through epigenetic reprogramming and senolytics.

Key Technologies

• Epigenetic reprogramming: Uses transcription factors to alter DNA methylation and reverse cellular aging without changing cell type. Startups like Altos Labs and Retro Biosciences are leading this.
• Senolytics: Drugs that clear senescent cells, which secrete inflammatory signals, reducing age-related diseases like cancer. Companies such as Unity Biotechnology are developing small molecules and biologics.
• Improved drug discovery with AI: AI models screen large datasets to identify targets for longevity therapies, e.g., via epigenetic reprogramming or repurposing existing drugs. Insilico Medicine is a leader in using AI to optimize drug design.

Applications

• Neurodegeneration: Targets aging in the brain, e.g., using senolytics to reduce neuroinflammation for Alzheimer's and Parkinson's.
• Cardiovascular aging: Interventions target atherosclerosis and heart failure through senolytics, telomerase therapy, or rapamycin.
• Cancer prevention: Strategies include eliminating senescent cells and enhancing immune surveillance to reduce mutation risks.
• Age-related immune decline: Rejuvenation methods like thymus regeneration or stem-cell therapies improve immune function and reduce infection risk.
• Other areas: Metabolic disorders, osteoporosis, and macular degeneration could benefit from broad anti-aging therapies.

Limitations

• Scientific complexities: Aging's multifaceted nature makes R&D challenging, with animal successes not always translating to humans. Biomarkers for biological age are lacking, prolonging trials.
• Regulatory obstacles: Aging is not classified as a disease, forcing companies to seek narrow indications like frailty. Demonstrating long-term effects requires lengthy trials, and safety standards for healthy populations are stricter.
• Commercial uncertainties: No market-approved therapies exist, deterring traditional pharma investment. Funding relies on specialized funds and billionaires. Public trust issues from past anti-aging pseudoscience and uncertainties in pricing/reimbursement persist.

Market Outlook and Investment

The market is driven by an aging global population and demand for health-span extension. VC investment fluctuates: it peaked at ~$794M in 2021, dropped to ~$148M in 2023, and rebounded to ~$294M in 2024 (excluding large raises like Altos Labs' $3B). High-profile backers amplify momentum. Key deals include NewLimit's $72.3M in 2025. Growth is expected from niche applications, with potential for broad adoption if clinical trials validate effects, but risks like setbacks or regulatory delays loom large. Long-term potential mirrors oncology, aiming for systemic aging interventions.

Quantitative Highlights

• Funding Trends: Global VC investment in longevity tech saw fluctuations, with $294M in 2024. Top companies like Altos Labs ($5.565B raised) and Unity Biotechnology ($355.3M) lead.
• Key Metrics: Companies raised varying funding, with high Exit Predictor Scores for firms like Gordian Biotechnology and Rejuvenation Technologies, indicating strong M&A potential.
• Patents: Leaders include Unity Biotechnology and Calico, highlighting innovation in aging research.

Recommendations and Future

Despite hurdles, longevity tech holds transformative potential for healthcare by shifting from disease-specific treatments to preventative aging interventions. Success depends on clinical validation, regulatory acceptance, and ethical considerations for equitable access. The sector could redefine aging and extend healthy lifespans, with the next decade crucial for breakthroughs.